MX2022010234A - Metodos y reactivos para el diagnostico de la infeccion por coronavirus del sindrome respiratorio agudo severo 2 (sars-cov-2). - Google Patents

Metodos y reactivos para el diagnostico de la infeccion por coronavirus del sindrome respiratorio agudo severo 2 (sars-cov-2).

Info

Publication number
MX2022010234A
MX2022010234A MX2022010234A MX2022010234A MX2022010234A MX 2022010234 A MX2022010234 A MX 2022010234A MX 2022010234 A MX2022010234 A MX 2022010234A MX 2022010234 A MX2022010234 A MX 2022010234A MX 2022010234 A MX2022010234 A MX 2022010234A
Authority
MX
Mexico
Prior art keywords
antibody
infection
cov
sars
seq
Prior art date
Application number
MX2022010234A
Other languages
English (en)
Inventor
Katja Steinhagen
Claudia Messing
Erik Lattwein
Konstanze Stiba
Fabian Lindhorst
Eva Neugebauer
Marcel Müller
Victor Corman
Original Assignee
Euroimmun Medizinische Labordiagnostika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20158626.0A external-priority patent/EP3715847A1/en
Application filed by Euroimmun Medizinische Labordiagnostika Ag filed Critical Euroimmun Medizinische Labordiagnostika Ag
Publication of MX2022010234A publication Critical patent/MX2022010234A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Abstract

La presente invención se refiere a un método para diagnosticar una infección por SARS-CoV-2 que comprende el paso de detectar la presencia o ausencia de un anticuerpo contra la SEC ID NO: 1, preferentemente de clase IgA, en una muestra de un sujeto, un método para el diagnóstico diferencial de una infección por coronavirus, un uso de un anticuerpo contra la SEC ID NO: 1, preferiblemente un anticuerpo de clase IgA para diagnosticar una infección por SARS-CoV-2 o para el diagnóstico diferencial de una infección por coronavirus, preferiblemente para distinguir entre una infección por SARSCoV-2, MERS y NL63, 229E, OC43 y HKU1, y un kit que comprende un polipéptido que comprende SEC ID NO: 1 o una variante del mismo, preferiblemente recubierto a un portador de utilidad diagnóstica y uno o más, preferiblemente todos los reactivos del grupo que comprende un anticuerpo contra la SEC ID NO: 1, un amortiguador de lavado, un medio para detectar la presencia de un anticuerpo, preferible-mente de clase IgA, preferiblemente un anticuerpo secundario que se une específicamente a los anticuerpos de clase IgA, preferiblemente que comprende una etiqueta detectable, y un amortiguador de dilución.
MX2022010234A 2020-02-19 2021-02-19 Metodos y reactivos para el diagnostico de la infeccion por coronavirus del sindrome respiratorio agudo severo 2 (sars-cov-2). MX2022010234A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20158348 2020-02-19
EP20158626.0A EP3715847A1 (en) 2020-02-20 2020-02-20 A method and reagents for the diagnosis of sars-cov-2
EP20158821 2020-02-21
DE202020003564 2020-08-20
DE202020104982 2020-08-28
PCT/EP2021/054113 WO2021165448A1 (en) 2020-02-19 2021-02-19 Methods and reagents for diagnosis of sars-cov-2 infection

Publications (1)

Publication Number Publication Date
MX2022010234A true MX2022010234A (es) 2022-11-16

Family

ID=74591943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010234A MX2022010234A (es) 2020-02-19 2021-02-19 Metodos y reactivos para el diagnostico de la infeccion por coronavirus del sindrome respiratorio agudo severo 2 (sars-cov-2).

Country Status (14)

Country Link
US (1) US20210190797A1 (es)
EP (2) EP3978927A3 (es)
JP (1) JP7022969B2 (es)
KR (1) KR102570713B1 (es)
CN (1) CN113557431A (es)
AU (1) AU2021223701B2 (es)
BR (1) BR102021003012A2 (es)
CA (1) CA3109607C (es)
DE (2) DE202021100842U1 (es)
ES (1) ES2822295T1 (es)
MX (1) MX2022010234A (es)
RU (1) RU2021134819A (es)
SG (1) SG11202112544XA (es)
WO (1) WO2021165448A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300251B (zh) * 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
CN113087777B (zh) * 2020-04-17 2023-05-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白以及用该蛋白制备的疫苗
US11644456B2 (en) * 2020-04-28 2023-05-09 Brandon Heeger Rapid testing mechanism and method for respiratory viral pathogens
IT202000009625A1 (it) * 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.
GB202006815D0 (en) * 2020-05-07 2020-06-24 Senseutics Ltd Method
WO2021222988A1 (en) * 2020-05-07 2021-11-11 Griffith University Cell entry-modulating agents and uses therefor
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
CN114057846B (zh) * 2020-08-07 2024-04-02 清华大学 一种预防新型冠状病毒感染covid-19的多肽、免疫原性偶联物及其用途
CN112028978B (zh) * 2020-09-07 2023-06-16 重庆医科大学 新冠病毒特异性cd8+t细胞表位肽及其应用
US20220139567A1 (en) * 2020-10-30 2022-05-05 The Boeing Company Methods for modeling infectious disease test performance as a function of specific, individual disease timelines
JP6976621B1 (ja) * 2021-02-04 2021-12-08 株式会社Icst 検査器具、検査キットおよび検査方法
KR102426782B1 (ko) * 2021-04-27 2022-07-28 국민대학교산학협력단 SARS-CoV-2 RBD 항원 특이적 항체를 포함하는 진단용 조성물 또는 키트
WO2022231320A1 (ko) * 2021-04-27 2022-11-03 국민대학교산학협력단 Sars-cov-2 s 단백질에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편, 및 이들의 용도
WO2023033363A1 (ko) * 2021-09-06 2023-03-09 국민대학교산학협력단 Sars-cov-2에 특이적으로 결합하는 이중특이적 항체
CN113046370B (zh) * 2021-05-31 2021-09-07 北京华芢生物技术有限公司 新型冠状病毒b．1．1．7英国突变株rbd的基因及其应用
WO2022253260A1 (zh) * 2021-06-01 2022-12-08 南京金斯瑞生物科技有限公司 新型冠状病毒及其突变株中和抗体的检测试剂盒
GB202110391D0 (en) 2021-07-19 2021-09-01 Tissue Click Ltd A detection kit and methods of detection of infectious agents
KR102602561B1 (ko) * 2021-09-16 2023-11-17 한국공학대학교산학협력단 2019 신종 코로나바이러스 중화항체 검출용 측면유동분석 기반의 바이오센서
CN113801963B (zh) * 2021-09-17 2024-03-26 佛山科学技术学院 一种检测冠状病毒的引物探针组合、试剂盒及方法
CN113929773B (zh) * 2021-10-08 2023-02-28 国际遗传工程和生物技术中心泰州区域研究中心 一种抗SARS-CoV-2 S1-RBD单克隆抗体及其应用
WO2023064631A1 (en) * 2021-10-15 2023-04-20 Chan Zuckerberg Biohub, Inc. Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing
CN114075553B (zh) * 2021-10-30 2023-10-03 西北工业大学 一种可用于新冠病毒中和抗体活性评价和作为核酸检测标准物的假病毒颗粒及其制备方法
CN114014940B (zh) * 2021-11-25 2022-11-15 华兰基因工程有限公司 一种2019-nCoV表面蛋白受体结合区融合蛋白制备方法
CN114262694B (zh) * 2021-12-06 2023-11-03 军事科学院军事医学研究院军事兽医研究所 以B型流感病毒为载体的SARS-CoV-2疫苗候选株及其构建方法和应用
CN114315990B (zh) * 2022-03-10 2022-05-27 北京康乐卫士生物技术股份有限公司 新型冠状病毒特异性单克隆抗体的制备及其应用
CN114774412A (zh) * 2022-03-15 2022-07-22 上海市东方医院（同济大学附属东方医院） 新冠病毒vmiRNA前体序列、新冠病毒vmiRNA及应用
CN114814216B (zh) * 2022-06-30 2022-10-18 中国科学院基础医学与肿瘤研究所(筹) 用于鉴别新冠核衣壳蛋白的核酸适体-抗体混合夹心法
WO2024029523A1 (ja) * 2022-08-02 2024-02-08 応用酵素医学研究所株式会社 コロナウイルス感染症の評価項目を判断するための情報を提供する方法
CN115951051B (zh) * 2022-10-18 2024-01-12 北京卓诚惠生生物科技股份有限公司 一种高灵敏度新型冠状病毒抗原胶体金检测试剂盒及其制备方法
CN117144063B (zh) * 2023-09-15 2024-04-19 果然基因科技(山东)股份有限公司 一种12种呼吸道病原体荧光pcr熔解曲线试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
TW200512457A (en) * 2003-06-10 2005-04-01 Agency Science Tech & Res Method of diagnosing SARS corona virus infection
CN1609617B (zh) * 2003-09-29 2012-02-15 香港中文大学 诊断与预防严重急性呼吸道综合症（sars）的组合物和方法
TWI303249B (en) * 2004-01-09 2008-11-21 Nat Health Research Institutes Receptor binding polypeptides
CN101039955A (zh) * 2004-06-04 2007-09-19 巴斯德研究院 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物
CA2568838A1 (en) * 2004-06-04 2005-12-15 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
US20060188519A1 (en) * 2004-06-14 2006-08-24 To Cheung Peptides, antibodies, and methods for the diagnosis of SARS
GB0725239D0 (en) 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
DE202011106093U1 (de) 2011-09-24 2011-10-19 Euroimmun Medizinische Labordiagnostika Ag Kalibrationsstreifen für einen Immunoblot
KR20150064104A (ko) 2012-09-23 2015-06-10 에라스무스 유니버시티 메디컬 센터 로테르담 사람 베타 코로나바이러스의 계통 c 및 이의 바이러스 수용체로서 n-말단 디펩티딜 펩티다아제의 확인
CN113624977A (zh) * 2020-05-09 2021-11-09 中国科学技术大学 SARS-CoV-2感染诊断方法
EP4105228A4 (en) * 2020-05-11 2023-10-11 Hengda Biomedical Technology Co., Ltd. ANTIGENIC POLYPEPTIDE OF SARS-COV-2, RECOMBINANT ADENO-ASSOCIATED VIRUS THEREOF, AND USE IN VACCINE PREPARATION
CN111518175B (zh) * 2020-05-11 2021-02-26 广东珩达生物医药科技有限公司 Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用

Also Published As

Publication number Publication date
SG11202112544XA (en) 2021-12-30
JP7022969B2 (ja) 2022-02-21
EP3978927A3 (en) 2022-06-22
WO2021165448A1 (en) 2021-08-26
US20210190797A1 (en) 2021-06-24
AU2021223701A1 (en) 2022-01-06
EP3809137A1 (en) 2021-04-21
RU2021134819A (ru) 2022-02-17
BR102021003012A2 (pt) 2021-11-30
DE202021100842U1 (de) 2021-08-17
CA3109607C (en) 2023-04-04
EP3978927A2 (en) 2022-04-06
AU2021223701B2 (en) 2022-05-19
KR20220006125A (ko) 2022-01-14
CA3109607A1 (en) 2021-05-20
KR102570713B1 (ko) 2023-08-25
JP2021167805A (ja) 2021-10-21
DE21158065T1 (de) 2021-06-10
CN113557431A (zh) 2021-10-26
ES2822295T1 (es) 2021-04-30
RU2021134819A3 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
MX2022010234A (es) Metodos y reactivos para el diagnostico de la infeccion por coronavirus del sindrome respiratorio agudo severo 2 (sars-cov-2).
Cavalera et al. A multi-target lateral flow immunoassay enabling the specific and sensitive detection of total antibodies to SARS COV-2
CN112229994B (zh) 一种基于磁微粒化学发光的新型冠状病毒抗体检测试剂盒
EP3869200A1 (en) A method and reagents for the diagnosis of sars-cov-2
Theel The past, present, and (possible) future of serologic testing for Lyme disease
Pereira et al. A combined enzyme immunoassay for rotavirus and adenovirus (EIARA)
EP4138913A1 (en) Rapid, point of care detection of neutralizing antibodies against a virus
US20230228752A1 (en) Kits and methods for the enrichment and detection of RNA viruses of the Coronaviridae family
Granade et al. Rapid detection and differentiation of antibodies to HIV-1 and HIV-2 using multivalent antigens and magnetic immunochromatography testing
Hamkar et al. Assessment of IgM enzyme immunoassay and IgG avidity assay for distinguishing between primary and secondary immune response to rubella vaccine
CN103917874B (zh) 改进的疫苗诊断
Van der Heijden First international ring trial of ELISAs for Salmonella-antibody detection in swine
US9689873B2 (en) Method for diagnosing and differentiating HIV-2 infections
ATE200709T1 (de) Htlv-i/htlv-ii assay und verfahren
Kwang et al. Serological diagnosis of caprine lentivirus infection by recombinant immunoassays
EP2023142A1 (en) Immunoassay utilizing recombinant nucleocapsid-proteins for detection of antibodies to human coronaviruses
Du et al. Development and application of an indirect ELISA for the detection of gp45 antibodies to equine infectious anemia virus
WO2021217140A3 (en) Specificity enhancing reagents for covid-19 antibody testing
KR20140132410A (ko) 간섭 펩티드 및 미생물 검출 방법
WO2021240425A1 (en) A method for rapid detection of antibodies against sars-cov-2 using recombinant nucleospike fusion protein
US20230358746A1 (en) METHODS AND KITS FOR DETERMINING SEROSTATUS OF SARS-CoV-2
Soleimani et al. Usefulness of a multiplex immunodot in case of discordant results between automated COVID-19 serological assays
Kumari et al. Development and validation of novel kit for quantification of SARS-CoV-2 antibodies on clinical samples
EP3922262A1 (en) Assay for the detection of the cys-like protease (mpro) of sars-cov-2
Shankaran et al. Detection of immunoglobulins G and M to rubella virus by time-resolved immunofluorometry